We refer to your Company’s announcement dated 17 August 2020 in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-
1) To provide the specific roles and responsibilities of BKCB and Generex respectively under the collaboration.
2) To state the estimated total capital and investment outlay, and the source of funds for the collaboration.
3) What is the stage of development and clinical trials of the Covid-19 Vaccine developed by Generex and whether necessary approvals have been obtained from the relevant government/medical authorities. If yes, to provide the name thereof.
4) To elaborate on the strategy that the parties had laid down in the preparation of the Project. 5) To provide further details on the"li-Key immune system activation technology". 6) Please explain whether BKCB has the required and relevant expertise in the medical field to undertake the relevant production and/or distribution of the Covid-19 Vaccine. If yes, to provide the background information such as educational, nationality and past working experiences of such person. In addition, to also provide the following additional information (where relevant):- (i) details of the production facilities, including the location, production capacity and whether such facilities are subject to any government authorities' approval/consent; and (ii) the distribution channel for the sale of the Covid-19 Vaccine. 7) Risk factors in relation to the collaboration that BKCB may be exposed to and the mitigating factors. 8) The target market under the collaboration and whether any contract has been secured. 9) Whether necessary approval have been obtained for distribution and marketing of the Covid-19 Vaccine. Please furnish Bursa Securities with your reply within one (1) market day from the date hereof. Yours faithfully, Listing Regulation
Cc : Market Surveillance Dept. , Securities Commission (via fax) |